CBIO
Crescent Biopharma Inc
$
13.110
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
13.500
Open
12.610
VWAP
13.18
Vol
155.67K
Mkt Cap
182.13M
Low
12.610
Amount
2.05M
EV/EBITDA(TTM)
--
Total Shares
13.89M
EV
33.49M
EV/OCF(TTM)
--
P/S(TTM)
--
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
Show More
4 Analyst Rating
Wall Street analysts forecast CBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBIO is 23.25 USD with a low forecast of 18.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.110
Low
18.00
Averages
23.25
High
28.00
Current: 13.110
Low
18.00
Averages
23.25
High
28.00
Jefferies
NULL
to
Buy
initiated
$26
2025-08-25
Reason
Jefferies
Price Target
$26
2025-08-25
initiated
NULL
to
Buy
Reason
Jefferies initiated coverage of Crescent Biopharma with a Buy rating and $26 price target. Crescent is a preclinical-stage oncology company with CR-001 as its lead asset, the analyst tells investors in a research note. Jefferies believes in the PD-(L)1xVEGF class and sees an \"intriguing\" risk/reward at current share levels.
H.C. Wainwright
NULL -> Buy
initiated
$25
2025-08-11
Reason
H.C. Wainwright
Price Target
$25
2025-08-11
initiated
NULL -> Buy
Reason
H.C. Wainwright initiated coverage of Crescent Biopharma with a Buy rating and $25 price target. The company's lead asset, CR-001, is a bispecific antibody targeting programmed cell death protein 1 and vascular endothelial growth factor, the analyst tells investors in a research note. The firm sees an attractive valuation at current share levels and views Crescent as a potential takeover target.
Wedbush
Outperform
initiated
$27
2025-07-14
Reason
Wedbush
Price Target
$27
2025-07-14
initiated
Outperform
Reason
Wedbush initiated coverage of Crescent Biopharma with an Outperform rating and $27 price target. The firm says Crescent is an oncology-focused company developing programs for the treatment of solid tumors. Wedbush expects the company's additional topoisomerase-1 inhibitor-based antibody drug conjugate programs CR-002 and CR-003 to allow for synergistic combinations with CR-001 and drive "differentiated activity with validated mechanisms."
Stifel
Buy
initiated
$28
2025-06-24
Reason
Stifel
Price Target
$28
2025-06-24
initiated
Buy
Reason
Stifel initiated coverage of Crescent Biopharma with a Buy rating and $28 price target. The stock represents an attractive opportunity to gain rationally-valued exposure/leverage to the emerging PD-1xVEGF bispecific class now poised to potentially displace/expand a greater than$50B PD-1-targeting mAb market, the analyst tells investors in a research note. Stifel adds that its $7.5B+ peak sales estimate across lung/GI/gynecological malignancies reflects its belief that "thoughtful" indication selection and clinical execution can yield meaningful CR-001-based value creation in the absence of any biological and mechanistic differentiation.
TD Cowen
TD Cowen
Buy
initiated
2025-06-21
Reason
TD Cowen
TD Cowen
Price Target
2025-06-21
initiated
Buy
Reason
TD Cowen initiated coverage of Crescent Biopharma with a Buy rating and no price target. Crescent develops "best-in-class" molecules for validated oncology targets, the analyst tells investors in a research note. The firm says the company's lead asset CR-001 is a PD-1 x VEGF bispecific with potential to advance standard of care in solid tumors such as non-small cell lung cancer, a $15B market. Proof of concept data for CR-001 is expected by the second half of 2026, "which could be a significant value inflection point," contend TD.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Crescent Biopharma Inc (CBIO.O) is -1.31, compared to its 5-year average forward P/E of -2.23. For a more detailed relative valuation and DCF analysis to assess Crescent Biopharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.23
Current PE
-1.31
Overvalued PE
-0.09
Undervalued PE
-4.37
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
+103.04%
-21.03M
Operating Profit
FY2025Q2
YoY :
+115.84%
-21.79M
Net Income after Tax
FY2025Q2
YoY :
-63.92%
-5.65
EPS - Diluted
FY2025Q2
YoY :
+150.53%
-22.29M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CBIO News & Events
Events Timeline
2025-07-31 (ET)
2025-07-31
07:36:49
Crescent Biopharma sees cash runway through 2027
2025-07-31
07:36:27
Crescent Biopharma reports Q2 EPS ($4.93)
2025-07-08 (ET)
2025-07-08
07:32:32
Crescent Biopharma appoints Jan Pinkas as CSO
Sign Up For More Events
Sign Up For More Events
News
4.0
08-27BenzingaHC Wainwright & Co. Affirms Buy Rating for Crescent Biopharma, Keeps $25 Price Target Intact
4.0
08-25BenzingaDevon Energy Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday
9.5
07-31NewsfilterCrescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Sign Up For More News
People Also Watch
NVDA
NVIDIA Corp
183.610
USD
+3.93%
META
Meta Platforms Inc
765.160
USD
-1.70%
TSLA
Tesla Inc
434.210
USD
+1.91%
MSFT
Microsoft Corp
514.450
USD
-0.67%
AMZN
Amazon.com Inc
227.630
USD
-1.66%
AAPL
Apple Inc
256.080
USD
+4.31%
ORCL
Oracle Corp
328.150
USD
+6.31%
AVGO
Broadcom Inc
338.790
USD
-1.78%
XOM
Exxon Mobil Corp
112.020
USD
-0.71%
WMT
Walmart Inc
102.820
USD
+0.48%
FAQ
What is Crescent Biopharma Inc (CBIO) stock price today?
The current price of CBIO is 13.11 USD — it has increased 1.47 % in the last trading day.
What is Crescent Biopharma Inc (CBIO)'s business?
What is the price predicton of CBIO Stock?
What is Crescent Biopharma Inc (CBIO)'s revenue for the last quarter?
What is Crescent Biopharma Inc (CBIO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Crescent Biopharma Inc (CBIO)'s fundamentals?
How many employees does Crescent Biopharma Inc (CBIO). have?